Related Experiment Video
Updated: Feb 18, 2026
Subcutaneous Administration of Muscarinic Antagonists and Triple-Immunostaining of the Levator Auris Longus Muscle in Mice
Published on: September 8, 2011
Muscarinic receptor subtype distribution in the central nervous system and relevance to aging and Alzheimer's disease
E P Lebois1, C Thorn1, J R Edgerton1
1Internal Medicine Research Unit, Pfizer, Inc., Cambridge, MA, United States.
Abstract:
Muscarinic acetylcholine receptors (mAChRs) are G proteincoupled receptors (GPCRs) that mediate the metabotropic actions of acetylcholine (ACh). There are five subtypes of mAChR, M1 - M5, which are expressed throughout the central nervous system (CNS) on numerous cell types and represent promising treatment targets for a number of different diseases, disorders, and conditions of the CNS. Although the present review will focus on Alzheimer's disease (AD) and amnestic mild cognitive impairment (aMCI), a number of conditions such as Parkinson's disease (PD), schizophrenia, and others represent significant unmet medical needs for which selective muscarinic agents could offer therapeutic benefits. Numerous advances have been made regarding mAChR localization through the use of subtype-selective antibodies and radioligand binding studies and these efforts have helped propel a number of mAChR therapeutics into clinical trials. However, much of what we know about mAChR localization in the healthy and diseased brain has come from studies employing radioligand binding with relatively modest selectivity. The development of subtype-selective small molecule radioligands suitable for in vitro and in vivo use, as well as robust, commercially-available antibodies remains a critical need for the field. Additionally, novel genetic tools should be developed and leveraged to help move the field increasingly towards a systems-level understanding of mAChR subtype action. Finally, functional, proteomic, and genetic data from ongoing human studies hold great promise for optimizing the design and interpretation of studies examining receptor levels by enabling patient stratification. This article is part of the Special Issue entitled 'Neuropharmacology on Muscarinic Receptors'.
Insights
Muscarinic acetylcholine receptors (mAChRs) are key targets for central nervous system (CNS) disorders like Alzheimer's disease. Developing selective agents and better tools is crucial for advancing mAChR-based therapies.
Area of Science:
- Neuroscience
- Pharmacology
- Receptor Biology
Background:
- Muscarinic acetylcholine receptors (mAChRs), a class of G protein-coupled receptors (GPCRs), mediate acetylcholine's actions in the central nervous system (CNS).
- Five subtypes (M1-M5) are widely expressed, presenting therapeutic potential for CNS disorders including Alzheimer's disease (AD), Parkinson's disease (PD), and schizophrenia.
- Current understanding of mAChR localization relies on methods with limitations in selectivity, hindering therapeutic development.
Purpose of the Study:
- To review the current state of knowledge regarding mAChR localization and therapeutic potential in CNS disorders.
- To highlight the need for improved tools, including subtype-selective radioligands and antibodies, for studying mAChRs.
- To emphasize the importance of genetic and proteomic data for a systems-level understanding and patient stratification.
Main Methods:
- Review of existing literature on mAChR localization studies.
- Analysis of advances in developing subtype-selective antibodies and radioligands.
- Discussion of novel genetic tools and their application in systems neuroscience.
Main Results:
- Significant progress has been made in identifying mAChR localization, leading to several mAChR therapeutics entering clinical trials.
- Existing methods for studying mAChR localization often lack sufficient selectivity.
- There is a critical need for more selective small molecule radioligands and robust antibodies for mAChR research.
Conclusions:
- Selective mAChR agents hold promise for treating various CNS disorders, particularly AD and amnestic mild cognitive impairment (aMCI).
- Advancements in tool development, including radioligands and antibodies, are essential for further progress.
- Integrating functional, proteomic, and genetic data from human studies will optimize therapeutic design and patient stratification.
More Related Videos
09:15Stereological Estimation of Cholinergic Fiber Length in the Nucleus Basalis of Meynert of the Mouse Brain
Published on: February 5, 2020
07:02A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
Published on: February 11, 2019
Related Concept Videos
01:25Cholinergic Receptors: Muscarinic
The subtypes M1, M3, and M5 couple with the Gq subunit and activate the phospholipase C (PLC) activity, mobilizing intracellular Ca2+....
01:15Cholinergic Receptors: Nicotinic
There are two types of nicotinic receptors: neuromuscular (NM/NM/N1) and neuronal (NN/NN/N2). The two families differ based on their location and selectivity to...
01:28Cholinergic Antagonists: Pharmacological Actions
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
01:30Ligand-Gated Ion Channel Receptor: Gating Mechanism
01:31Adrenergic Receptors: ɑ Subtype
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
00:59Direct-Acting Cholinergic Agonists: Pharmacological Actions